Raptor Pharmaceutical has announced its acquisition of Quinsair, a therapy used to treat bacterial lung infections common in cystic fibrosis.
In addition to cystic fibrosis, Quinsair has development potential in two additional orphan diseases with significant unmet needs, bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections, for which there is a lack of treatment options.
“The acquisition of Quinsair adds another significant product to our rare disease franchise,” stated Julie Anne Smith, president and CEO of Raptor. “We are excited about our plans to launch the drug in Europe and Canada beginning in the first half of 2016, initiate a clinical program in 2016 in at least one of nontuberculous mycobacteria and/or bronchiectasis and engage with the FDA regarding a path to potential approval in the U.S. in cystic fibrosis.”
The acquisition of Quinsair was completed through Raptor’s entirely held subsidiary, Raptor Pharmaceuticals Inc.
Tripex received nearly $34.2 million in cash consideration with the product acquisition, subject to representation costs and warranty insurance payment deductions. In return, Raptor gains exclusive worldwide assets and rights to develop, manufacture and commercialize the drug formulation.